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The puzzling in¯ ammatory bowel disease: growing interest for mediators
of in¯ ammation
In this issue of Mediators of In￿ ammation two
review articles and one research paper describe
the local in￿ammation in the colon and the role
of cytokines, leukocyte migration and the effect
of cell± cell interaction on cytokine synthesis. In
the paper by Beck and Wallace an overview is
given of so far known important pro-in￿amma-
tory cytokines (IL-1, IL-2, IL-5, IL-6, IL-8, TNFa
and IFNc) and anti-in￿ammatory cytokines (IL-4,
IL-10, IL-11, IL-13 and TGFb).1 In addition the
migration of leukocytes, mediated by adhesion
molecules such as selectins, chemokines and
integrins, is reviewed by van Rees et al.2 During
or after this migration lymphocytes could stimu-
late the synthesis of the pro-in￿ammatory cyto-
kines IL-2 and IFNc, as described by Hoang et
al.3
Recently it has been described by Smith et al.
that IL-1b stimulates the LPS-induced PGE2
synthesis by the colonocyte cell line CACO-2,
whereas LTB4 was uneffected.4 After simultan-
eous incubation with IL-1ra the elevated levels
of PGE2 were completely abolished, although a
signi￿cant increase in LTB4 was observed. This
could be due to the lack of feedback inhibition
by substantial amounts of PGE2.
In the December 1995 issue of Mediators of
In￿ ammation two debate articles on the invol-
vement of nitric oxide as pro- or anti-in￿amma-
tory mediator were published,5,6 again re￿ecting
Janus, the symbol for mediators of in￿amma-
tion, which exert both harmful and bene￿cial
functions.
In summary, from the above-mentioned ￿nd-
ings it could be concluded that in in￿ammatory
bowel disease (IBD) mediators of in￿ammation
are involved which could be considered as (a)
pro-or anti-in￿ammatory mediators, (b) primary
or secondary mediators, (c) proteins, lipid
mediators or otherwise, (d) T H1- or T H2-cell
derived substances. Furthermore migrated cells
could amplify synthesis of mediators by cells
localized in the lamina propia. Moreover one
should consider that IBD include two different
diseases (Crohn’s disease and ulcerative colitis)
which, though displaying similar aspects of
in￿ammatory features in the colon, nevertheless
require distinct medical treatment.
The adequate therapy of patients not respond-
ing to classical treatment with corticosteroids
nowadays includes the experimental use of anti-
TNFa and IL-10 in Crohn’s disease,7,8 whereas
nicotine also has proven to be bene￿cial in
ulcerative colitis.9 Such treatment regimens
imply knowledge about mechanisms of action
underlying biochemical aspects of acute, sub-
acute and chronic phenomena of colonic in-
￿ammation.
So far we may conclude that corticosteroids
will suppress all mediators, whereas 5-amino-
salicylic acid (5-ASA) partly attenuates cytokine
synthesis. Although nicotine probably acts
through inhibition of eicosanoids and pro-in-
￿ammatory cytokines,10,11 it is not yet clear why
nicotine (including the otherwise harmful habit
of smoking) is good for ulcerative colitis and
bad for Crohn’s disease.12 This could be related
to the T H1-and T H2-cell speci￿c aspects seen in
IBD.13 On the other hand con￿icting results
were obtained from investigations in Crohn’s
disease and ulcerative colitis in which IFNc, IL-2
and IL-10 were all increased.14,15
Up to now it is not quite clear whether
nicotine selectively inhibits pro-in￿ammatory
cytokines derived from T H1-cells or not, since
we observed that IL-10 was decreased after
nicotine in vivo.13
Finally cyclosporin has been reported to be
effective in IBD. Both T cell proliferation and
the production of T cell-derived cytokines is
inhibited.16 The reduction of T cell migration
might be another fruitful area for future stud-
ies.2,17
Knowledge of the potential T -cell subsets to
Mediators of In¯ ammation ´ Vol 6 ´ 1997 83generate pro- and anti-in￿ammatory cytokines
in IBD, which in turn affect secondary media-
tors such as eicosanoids, could contribute to
the understanding of these puzzling diseases
and subsequently lead to the development of
more adequate medicines to prevent severe
exacerbations during the chronic phase of the
disease.
Submission of research papers on this subject
would be welcomed for forthcoming issues of
Mediators of In￿ amm ation.
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